Zelira Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Zelira Therapeutics's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 3.5% per year.

Wichtige Informationen

-41.7%

Wachstumsrate der Gewinne

-20.6%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie31.2%
Wachstumsrate der Einnahmen-3.5%
Eigenkapitalrenditen/a
Netto-Marge-38,513.0%
Letzte Ertragsaktualisierung30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Jul 14
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Jan 19
Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Sep 25
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Jun 03
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Dec 31
A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Aufschlüsselung der Einnahmen und Ausgaben

Wie Zelira Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

ASX:ZLD Einnahmen, Ausgaben und Erträge (AUD Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Jun 240-3723
31 Mar 240-3632
31 Dec 230-3641
30 Sep 230-2141
30 Jun 230-651
31 Mar 231-882
31 Dec 221-10102
30 Sep 221-11112
30 Jun 222-12121
31 Mar 221-11101
31 Dec 211-1081
30 Sep 211-982
30 Jun 211-972
31 Mar 210-863
31 Dec 200-854
30 Sep 200-854
30 Jun 200-744
31 Mar 200-633
31 Dec 191-433
30 Sep 191-423
30 Jun 191-422
31 Mar 191-312
31 Dec 180-312
30 Sep 180-312
30 Jun 180-212
31 Mar 180-212
31 Dec 170-211
30 Sep 170-411
30 Jun 170-621
31 Dec 160-520
30 Jun 160000

Qualität der Erträge: ZLD is currently unprofitable.

Wachsende Gewinnspanne: ZLD is currently unprofitable.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.

Beschleunigtes Wachstum: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Erträge im Vergleich zur Industrie: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Eigenkapitalrendite

Hohe Eigenkapitalrendite: ZLD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren